74 in MCF-7aro cells: a microarray approach. Mol Cancer Res 3:203–218 27. DeBoer R, Burris H, Monnier A, Mouridsen H, O’Shaughnessy J, McIntyre K, Pritchard K, Smith I, Yardley D, on behalf of the H2H trial steering committee (2006) The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol 24(18S):582s. Abstract 10672 28. McArthur HL, Olivotto I, Gelmon KA, Speers CH, Chia S, Ellard S, Kennecke HF (2005) Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res Treat 94(Suppl 1):S124. Abstract 3001 29. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717 30. National Cancer Institute. Comparison trial of letrozole to anas- trozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00248170 31. National Cancer Institute. Exemestane, letrozole, or anastrozole in treating postmenopausal women who are undergoing surgery for stage II or stage III breast cancer. http://www.clinicaltrials. gov/ct/show/NCT00265759 32. National Cancer Institute. Exemestane or anastrozole in treating postmenopausal women who have undergone surgery for primary breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00066573 Breast Cancer Res Treat (2007) 105:67–74 33. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministra- tion of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764 34. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39 35. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen bio- transformation is associated with clinical outcomes of efﬁcacy and hot ﬂashes. J Clin Oncol 23:9312–9318 36. Gonzalez-Santiago S, Zarate R, de la Haba-Rodriguez J, Gomez A, Bandres E, Borrega P, Garcia-Foncillas J, Aranda E (2006) Genetic polymorphism CYP2D6(*4) interaction in clinical out- comes of tamoxifen-treated breast cancer patients. Ann Oncol 17(Suppl 9):ix56–ix68. Abstract 114P 37. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65:11071–11082 123